NGM Biopharmaceuticals (NGM) Stock Price, News & Analysis

Company Overview

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company develops NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced metastatic solid tumors; and Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of primary sclerosing cholangitis and non-alcoholic steatohepatitis. It also develops NGM120, an GFRAL antagonist antibody, which is in Phase II clinical trial to treat hyperemesis gravidarum; NGM831 and NGM438 which is in phase I/II clinical trial for the treatment of advanced solid tumors; and NGM621, an monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck to focus primarily on the identification, research and development of collaboration compounds directed to targets in the fields of ophthalmology and cardiovascular or metabolic, or CVM, disease, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $1.54 to $1.57
• 50-Day Range: $1.52 to $1.63
• 52-Week Range: $0.60 to $4.69
• Volume: 2.39 million shs
• Average Volume: 1.47 million shs
• Market Capitalization: $128.53 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.55
• Consensus Rating: Hold

NGM Biopharmaceuticals Stock Analysis - MarketRank™

NGM Biopharmaceuticals scored higher than 22% of companies evaluated by MarketBeat, and ranked 847th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

NGM Biopharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.

Amount of Analyst Coverage

NGM Biopharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for NGM Biopharmaceuticals are expected to grow in the coming year, from ($0.93) to ($0.78) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of NGM Biopharmaceuticals is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NGM Biopharmaceuticals is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

NGM Biopharmaceuticals has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for NGM.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NGM Biopharmaceuticals does not currently pay a dividend.

Dividend Growth

NGM Biopharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.54

Short Interest

There is no current short interest data available for NGM.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for NGM Biopharmaceuticals this week, compared to 1 article on an average week.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NGM Biopharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

35.90% of the stock of NGM Biopharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

75.74% of the stock of NGM Biopharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NGM Stock Analysis - Frequently Asked Questions

How were NGM Biopharmaceuticals' earnings last quarter?

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) issued its quarterly earnings data on Thursday, November, 4th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.34) by $0.03. The company had revenue of $18.58 million for the quarter, compared to the consensus estimate of $18.90 million. NGM Biopharmaceuticals had a negative trailing twelve-month return on equity of 77.85% and a negative net margin of 3,223.34%.

When did NGM Biopharmaceuticals IPO?

NGM Biopharmaceuticals (NGM) raised $100 million in an initial public offering on Thursday, April 4th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Cowen acted as the underwriters for the IPO.

What other stocks do shareholders of NGM Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NGM Biopharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Adobe (ADBE), Advanced Micro Devices (AMD), Broadcom (AVGO), CymaBay Therapeutics (CBAY) and PayPal (PYPL).

Company Calendar

• Last Earnings: 11/04/2021
• Today: 12/23/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:NGM
• CUSIP: N/A
• CIK: 1426332
• Web: www.ngmbio.com
• Phone: (650) 243-5555
• Fax: N/A
• Employees: 138
• Year Founded: 1998

Price Target and Rating

• Average Stock Price Target: $1.55
• High Stock Price Target: $1.55
• Low Stock Price Target: $1.55
• Potential Upside/Downside: +0.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.72)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-142,380,000.00
• Net Margins: -3,223.34%
• Pretax Margin: -3,223.34%
• Return on Equity: -77.85%
• Return on Assets: -67.76%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.79
• Quick Ratio: 7.79

Sales & Book Value

• Annual Sales: $4.42 million
• Price / Sales: 29.10
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.80 per share
• Price / Book: 0.86

Miscellaneous

• Outstanding Shares: 83,462,000
• Free Float: 53,499,000
• Market Cap: $128.53 million
• Optionable: Optionable
• Beta: 1.27